Hsu WF, Tsai PC, Chen CY, et al. - This study was carried out to evaluate whether hepatitis C virus (HCV) eradication reduces the risks of liver cirrhosis and cirrhosis‐related complications. Researchers performed a nationwide HCV registry cohort (Taiwanese chronic hepatitis C cohort) from 23 hospitals in Taiwan recruited between 2003 and 2015. For this analysis, 10,693 individuals with chronic hepatitis C (CHC) were included, linked to the Taiwan National Health Insurance Research Database, receiving pegylated interferon and ribavirin (PR) therapy for at least 4 weeks for new‐onset liver cirrhosis (LC) and liver‐related complications. It was shown that in noncirrhotic patients, HCV eradication with PR therapy reduced the incidence of new‐onset LC and the incidence of liver‐related complications in cirrhotic patients with CHC.